Form 8.3 - Abbvie Inc
March 09 2020 - 11:44AM
Dow Jones News
TIDM0QCV TIDM0Y7T
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING
1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) State Street Global Advisors &
Affiliates
--------------------------------------------- -------------------------------
Company dealt in AbbVie Inc.
--------------------------------------------- -------------------------------
Class of relevant security to which US$0.01 common stock
the dealings being disclosed relate (Note 2)
--------------------------------------------- -------------------------------
Date of dealing 6(th) March 2020
--------------------------------------------- -------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)
Long Short
------------------------------------- -------------------- -----------
Number (%) Number (%)
------------------------------------- ---------- -------- ------ ---
(1) Relevant securities 67,149,677 4.52960%
------------------------------------- ---------- -------- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------- ---------- -------- ------ ---
(3) Options and agreements to
purchase/sell N/A
------------------------------------- ---------- -------- ------ ---
Total 67,149,677 4.52960%
------------------------------------- ---------- -------- ------ ---
(b) Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)
Class of relevant security: Long Short
------------------------------------------- ----------- -----------
Number (%) Number (%)
------------------------------------------- ------ --- ------ ---
(1) Relevant securities N/A
------------------------------------------- ------ --- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------------- ------ --- ------ ---
(3) Options and agreements to purchase/sell N/A
------------------------------------------- ------ --- ------ ---
Total N/A
------------------------------------------- ------ --- ------ ---
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
-------------- ----------------------------- -----------------------
Purchase 2,800 88.82
-------------- ----------------------------- -----------------------
Purchase 135 89.15
-------------- ----------------------------- -----------------------
Purchase 2,664 88.82
-------------- ----------------------------- -----------------------
Purchase 25,896 88.82
-------------- ----------------------------- -----------------------
Purchase 17,928 88.82
-------------- ----------------------------- -----------------------
Purchase 291 88.82
-------------- ----------------------------- -----------------------
Purchase 202 88.82
-------------- ----------------------------- -----------------------
Purchase 5,652 88.82
-------------- ----------------------------- -----------------------
Purchase 1,260 88.82
-------------- ----------------------------- -----------------------
Purchase 26 88.82
-------------- ----------------------------- -----------------------
Purchase 2,500 88.82
-------------- ----------------------------- -----------------------
Purchase 704 88.82
-------------- ----------------------------- -----------------------
Purchase 2,300 88.37
-------------- ----------------------------- -----------------------
Purchase 488 88.82
-------------- ----------------------------- -----------------------
Sale 171,577 88.82
-------------- ----------------------------- -----------------------
Sale 1,160 88.82
-------------- ----------------------------- -----------------------
Sale 20,724 88.82
-------------- ----------------------------- -----------------------
Sale 1,980 88.20
-------------- ----------------------------- -----------------------
Sale 269 88.82
-------------- ----------------------------- -----------------------
Sale 807 88.82
-------------- ----------------------------- -----------------------
Sale 1,138 88.82
-------------- ----------------------------- -----------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
------------- --------------------- ----------------------------- --------------
N/A
------------- --------------------- ----------------------------- --------------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of Exercise Type, e.g. Expiry Option money
e.g. call option purchasing securities to which price American, date paid/received
varying etc. the option relates European etc. per unit (Note 5)
(Note 7)
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
N/A
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
----------------- -------------------- ------------------
N/A
----------------- -------------------- ------------------
(d) Other dealings (including transactions in respect of new securities)
(Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
--------------------- ------- -------------------------
N/A
--------------------- ------- -------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person
relating to the voting rights of any relevant securities
under any option referred to on this form or relating
to the voting rights or future acquisition or disposal
of any relevant securities to which any derivative
referred to on this form is referenced. If none, this
should be stated.
-----------------------------------------------------------
N/A
-----------------------------------------------------------
Is a Supplemental Form 8 attached? (Note 9) NO
------------------------------------------------------- -----------------
Date of disclosure 09(th) March 2020
------------------------------------------------------- -----------------
Contact name Lionel Colaco
------------------------------------------------------- -----------------
Telephone number 020 33956098
------------------------------------------------------- -----------------
If a connected EFM, name of offeree/offeror with which N/A
connected
------------------------------------------------------- -----------------
If a connected EFM, state nature of connection (Note N/A
10)
------------------------------------------------------- -----------------
(END) Dow Jones Newswires
March 09, 2020 11:29 ET (15:29 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Apr 2024 to May 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From May 2023 to May 2024
